Abbott has received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce stroke risk in patients with atrial fibrillation (AFib) by sealing the heart's left atrial appendage (LAA). The device improves on Abbott's previous model with a softer, more adaptable design to fit various LAA shapes and has shown strong safety and effectiveness in clinical trials. Following initial successful procedures in Europe, Abbott plans to expand the device's use across the continent. This approval adds to Abbott's growing portfolio of cardiac arrhythmia treatments aimed at stroke prevention.
Abbott received FDA De Novo authorization for Libre Duo 10 Day, the first wearable device that continuously monitors glucose and detects rising ketone levels, which can signal diabetic ketoacidosis. This regulatory milestone sets Abbott apart in diab...
Abbott has received FDA authorization for its Libre Duo 10 Day system, the world's first biowearable device that continuously monitors both glucose and ketone levels. This innovation helps people with diabetes detect rising ketones early, which can p...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
